Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Host factors

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    58 result(s) found for: Host factors. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-006577-25 Sponsor Protocol Number: 070101 Start Date*: 2007-07-25
    Sponsor Name:Karolinska Institutet
    Full Title: A prospective randomized study comparing rapamune and tacrolimus vs. cyclosporine and methotrexate as immune prophylaxis in allogeneic hematopoietic stem cell transplantation, using HLA-A, -B, -DRB...
    Medical condition: Graft versus host disease prophylaxis in patients receiving stem cell transplantation due to: chronic myeloid leukemia (CML) in 1st or 2nd chronic phase, acute myeloid leukemia (AML) in complete re...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018799 GVHD LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2004-000232-91 Sponsor Protocol Number: AP-AS-21-DE Start Date*: 2004-11-15
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: GvHD prophylaxis with ATG-Fresenius S in allogeneic Stem Cell Transplantation from matched unrelated donors: A randomised phase III multicenter trial comparing a standard GvHD prophylaxis with cycl...
    Medical condition: AML, ALL, MDS, CML
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005107-40 Sponsor Protocol Number: SNDX-6352-0504 Start Date*: 2021-08-24
    Sponsor Name:Syndax Pharmaceuticals, Inc.
    Full Title: AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active ...
    Medical condition: Recurrent/Refractory Active Chronic Graft Versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PT (Completed) GR (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003425-81 Sponsor Protocol Number: RLBUHT2763 Start Date*: 2007-03-29
    Sponsor Name:University of Liverpool
    Full Title: Host genetic factors influencing drug disposition and response to HIV treatment
    Medical condition: Pharmacogeneric study of HIV+ patients receiving antiretroviral therapy. We wish to correlate drug concentration with host genetic patients receiving certain HIV drugs. No dosage modification will...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-004108-16 Sponsor Protocol Number: HOFATA_v3.0 Start Date*: 2022-04-21
    Sponsor Name:Medical University Vienna
    Full Title: Host factors predicting target site concentration of antibiotics in critically ill patients: An explorative pharmacokinetic biomarker study
    Medical condition: All patients given standard of care intravenous therapy of the studied antibiotics will be screened against the inclusion criteria. Two groups are included: Group A (septic patients with organ dysf...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002096-96 Sponsor Protocol Number: NL57849.068.16 Start Date*: 2016-09-20
    Sponsor Name:Maastricht University Medical Center
    Full Title: TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia, a multicenter, open-label, non-randomized, controlled study (TOPIC-3 study)
    Medical condition: High-grade Cervical Intraepithelial Neoplasia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002876-32 Sponsor Protocol Number: AAD-CDD-001 Start Date*: 2008-10-06
    Sponsor Name:University of Wales Swansea
    Full Title: A multicentre, randomised, placebo controlled trial of lactic acid bacteria in the prevention of antibiotic-associated diarrhoea (AAD) and Clostridium difficile diarrhoea (CDD) in patients aged 65 ...
    Medical condition: AAD is diarrhoea occurring in association with antibiotic treatment without an alternative cause. It occurs typically 2-8 weeks after exposure to antibiotics. The frequency of AAD varies markedly b...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064065 Prophylaxis against diarrhoea PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006016-33 Sponsor Protocol Number: E410/2007 Start Date*: 2008-09-30
    Sponsor Name:Uniklinikum Tuebingen
    Full Title: Multicenter Phase II study of haploidentical hematopoietic cell transplantation with CD3/CD19 depleted grafts after a reduced intensity conditioning regimen for adult patients with acute leukemia
    Medical condition: Patients with acute leukemia with an indication for allogeneic HCT but without a suitable HLA-identical donor
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022052-23 Sponsor Protocol Number: ProtocolCodeGITMO-MF2010 Start Date*: 2011-04-20
    Sponsor Name:GITMO GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO,CELLULE STAMINALI EMOPOIETICHE E TERAPIA CELLULARE - ONLUS
    Full Title: Prospective, phase II randomized study to compare busulfan-fludarabine reduced-intensity conditioning (RIC) with thiotepa-fludarabine RIC regimen prior to allogeneic transplantation of hematopoieti...
    Medical condition: Primary or secondary myelofibrosis after essential thrombocytemia or polycyhemia vera
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000741-39 Sponsor Protocol Number: 6996 Start Date*: 2019-11-07
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: EFFECT OF AZITHROMYCIN ON THE PROPORTION OF FAILURES OF SEVERE PERIODONTITIS NON-SURGICAL TREATMENTS : A RANDOMIZED, DOUBLE-BLIND VERSUS PLACEBO STUDY
    Medical condition: Periodontology
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000763-33 Sponsor Protocol Number: 20160283 Start Date*: 2017-12-01
    Sponsor Name:Amgen, Inc.
    Full Title: A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Efavaleukin Alfa in Adult Subjects with Steroid Refractory Chronic Graft versu...
    Medical condition: Steroid Refractory Chronic Graft versus Host Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003938-14 Sponsor Protocol Number: MK-5592-069(P06200) Start Date*: 2013-04-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)
    Medical condition: Invasive aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10003488 Aspergillosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) LT (Prematurely Ended) PT (Completed) GB (Completed) EE (Completed) IT (Completed) PL (Completed) GR (Completed) FR (Completed) HU (Completed) CZ (Completed) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-003212-11 Sponsor Protocol Number: ITCC-101/APAL2020D Start Date*: 2022-02-17
    Sponsor Name:Princess Máxima Center
    Full Title: A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML
    Medical condition: Children, adolescents, and young adults up to the age of 21 years with acute myeloid leukemia with a documented negative test for FLT3/ITD mutation and either: - Untreated second relapse, who are s...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001941 AML LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) AT (Trial now transitioned) SE (Trial now transitioned) IE (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004250-17 Sponsor Protocol Number: RG_18-205,BN3010 Start Date*: 2019-10-11
    Sponsor Name:University of Birmingham
    Full Title: An International Prospective Trial on High-Risk Medulloblastoma in Patients Older than 3 Years
    Medical condition: Histologically proven high-risk medulloblastoma, with any of the currently defined histological subtypes. High-risk disease is defined as patients with sonic hedgehog (SHH) subgroup or non-SHH/non-...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) NO (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003970-89 Sponsor Protocol Number: CICL670ADE02 Start Date*: 2007-12-21
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to six months after allogeneic hematopoietic cell transplan...
    Medical condition: allogeneic hematopoietic cell transplantation with iron overload
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001756 Allogenic bone marrow transplantation therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005961-16 Sponsor Protocol Number: QVID-001 Start Date*: 2021-02-05
    Sponsor Name:Lars Jørgen Østergaard
    Full Title: Coenzyme Q10 as treatment for Long Term COVID-19 (The QVID study)
    Medical condition: Long Term COVID-19 illness
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-001001-14 Sponsor Protocol Number: IEO240 Start Date*: 2015-10-07
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: ¿A randomized placebo controlled phase II study with metformin in metabolic-unbalanced breast cancer survivors at higher risk for recurrence (MetBreCS)¿
    Medical condition: Metabolic-unbalanced breast cancer survivors at higher risk for recurrence (triple negative breast cancer, luminal B Her2 positive, non luminal HER2 positive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004418-17 Sponsor Protocol Number: I-BCT-1 Start Date*: 2014-05-07
    Sponsor Name:Oslo University Hospital
    Full Title: Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens.
    Medical condition: breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-003836-77 Sponsor Protocol Number: OCTO-003 Start Date*: 2008-12-09
    Sponsor Name:University of Oxford
    Full Title: AspECT - A phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia & oesophagitis.
    Medical condition: Barrett's Metaplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001282-17 Sponsor Protocol Number: E7389-G000-223 Start Date*: 2018-03-23
    Sponsor Name:Eisai Inc.
    Full Title: A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma S...
    Medical condition: Relapsed/Refractory Rhabdomyosarcoma Non-rhabdomyosarcoma Soft Tissue Sarcoma Ewing Sarcoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 27 02:16:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA